iDose TR

iDose TR (travoprost intracameral implant) is an FDA-approved drug-device combination product developed by Glaukos Corporation for the long-term reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The system consists of a micro-scale, medical-grade titanium implant that is surgically placed into the anterior chamber of the eye. It contains a proprietary, preservative-free formulation of 75 mcg of travoprost, a prostaglandin F2α analog. iDose TR is designed to provide continuous, 24/7 delivery of the medication directly into the eye for up to three years, effectively addressing the clinical challenges of patient non-adherence and ocular surface toxicity associated with daily topical eye drops. The drug works by acting as an agonist at prostaglandin F (FP) receptors, which increases the outflow of aqueous humor primarily through the uveoscleral pathway. In 2025, the FDA approved a labeling supplement allowing for repeat administration of the implant.

Brand names

iDose TR

Other names

travoprost intracameral implanttravoprost implanttravoprost 75 mcg implanttravoprost75 mcg implanttravoprost-75 mcg implant